Exchange: NASDAQ·Updated 04:10 PM EST
PRQR logo

PRQR ProQR Therapeutics N.V

$1.04
$0.01
(0.95%)
Today
Closed $1.04
$0.00
(0.00%)
After Hours
Reported EarningsNov 12
Mkt Cap$148.18M
Vol920,549.00

About PRQR

ProQR Therapeutics NV is a clinical stage biopharmaceutical company, which engages in the discovery and development of RNA therapies for the treatment of severe genetic rare diseases with a focus on inherited retinal diseases. The company was founded by Daniel Anton de Boer, Gerard J. Platenburg, Henri A. Termeer, and Domenico Valerio on February 21, 2012, and is headquartered in Leiden, the Netherlands.
59

Bullish Sentiment

How do you feel about PRQR?

Benitocalixto
$PRQR Aberdeen's Q3 13F Nov 6 filing for PRQR was a mistake - it showed 119,394 shares held. On November 10, Aberdeen re-filed an amendment stating the correct share count - 9,667,555 shares. Let's move on from this dumb rumor.
4
justfacts1
$PRQR Eli Lilly has paid $0 in collaboration milestone payments to ProQR Therapeutics (Nasdaq: PRQR) so far in 2026. Hopefully 🔜)
3
anlkrts
$PRQR it started to go down and down everyday after private meetings! Did something happen ?
1
johnnygogogo
$PRQR excited for another LLY acquisition of a private company (while ProQurians continue to work in the mines below LLY)
4
Benitocalixto
$PRQR there's been a lot of tax loss selling, no surprise. The only reason the stock is down here is because it's really easy to manipulate. This should be ending soon. The stock was at $2.30 per share in July, they raised money at $1.80 June, Insider buying was 1M shares at around $1.70, and things are so much better now with a December AX810 and an early January AX811. This will be the binary event. It's a good time to own smaller biotechs Nov-Feb, lots of biz development..
4
ehpats
$PRQR market cap 166m, cash 105m. Not much meat left on the bone for shorts unless they know bad data is on the way. But if the data is bad why are insiders buying big?
3
ehpats
$PRQR I way too early entering this one. Whis I was just jumping in now. Next 3-6 month window could be exceptional.
3
ehpats
$PRQR I wonder what Pete has planned for the third incarnation of Prqr. Maybe produce fly swatters or mouse traps?
1
anlkrts
$PRQR someone knows something we don’t know? Otherwise what is the explanation for this drop?
2
FutureInvesting777
$PRQR what is triggering the selling? These guys are known for not leaking data!!! Well! they did hire a Chief Data and AI Officer lately 🤔😆
2
Benitocalixto
$PRQR This valuation for PRQR is really disheartening. Comparing it to IBIO (definitely a comparable), including all warrants and options, the market cap is $135M and they have $76M in cash and equivalents. PRQR is so much more established with a big Pharma partner, a validated platform and lots of clinical data expected in the coming months. IBIO is basically a virtual company - has only 23 employees, it outsources all of its lab and clinical work and its CMO just left the company. How is it possible that PRQR and IBIO are valued so similarly?
1
dirkfrank
$PRQR they must be looking out of the window from time to time and see their value declining. End august the sp was 2.40$ Employee options etc. Major shareholders???
1
justfacts1
$PRQR Aberdeen’s 98.7% Exit: Seeing a top institutional buyer from Q2 reverse course and liquidate nearly its entire 8.9M-share position in Q3.
1
dirkfrank
$PRQR all things taken into consideration this is how it should go in the perfect world
1
Filvul
$PRQR The probability-weighted target price for ProQR Therapeutics (PRQR) under a bull-weighted scenario after January 2027 readout with a 15% net dilution discount is $2.84 per share. This implies an expected upside of +113.5% from the current $1.33 price. Key Numbers at a Glance • Current Price: $1.33. • Conservative (Diluted): $1.86 (+39.8% return). Assumes a 40% chance of weak or mixed data and cautious upside caps. • Bull Case (Diluted): $2.84 (+113.5% return). Gives a 75% chance to "Good" or "Strong" readouts with a 15% haircut for Phase 2 funding. • Bull Case (Undiluted): $3.34 (+150.9% return). Reflects strong data if ProQR avoids issuing new shares (e.g., via non-dilutive Eli Lilly milestone cash).
1
HeartOfTheCrow
$PRQR still no tangible progress with the Lilly partnership. Quarter after quarter of nothing.
1
smallcapexpert
$PRQR great results! Higher revenue and smaller loss on EPS on estimates. Expecting a verry 📈
1
anlkrts
$PRQR this mfrs are gonna go bankrupt I guess! What a waste of time! Seeing this going down and down everyday making me sick!
1
FutureInvesting777
$PRQR at this rate we may see historic lows of sub penny (.60s). Then, we will be dealing with a whole new set of challenges to overcome.
justfacts1
$PRQR short interest more than doubled from the end of Q2 2026 into Q3 and November 2026.

Advertisement|Remove ads.